United Therapeutics expands immune therapy pipeline with Thymmune

United Therapeutics Corporation has acquired Thymmune Therapeutics, a privately held preclinical biotechnology company, for $140 million in cash to expand its portfolio of regenerative thymic cell therapies. The acquisition includes potential earn-out payments of up to $160 million to former Thymmune equityholders, contingent on achieving clinical and regulatory milestones by the end of 2031. This strategic move aligns with United Therapeutics' mission to increase the supply of transplantable organs and develop immunomodulatory therapeutics for conditions such as post-transplant organ tolerance, immunodeficiencies, and autoimmune diseases. United Therapeutics reported cash and cash equivalents of $1.28 billion as of March 31, 2026.

Thymmune specializes in converting human-induced pluripotent stem cells (iPSC) into thymic cells, which mature in vivo to restore healthy T-cell function. The company's lead candidate, THY-100, is in preclinical development for congenital athymia, a life-threatening condition where infants are born without a functional thymus. Animal studies indicate THY-100 can facilitate the formation of a neo-thymus capable of supporting T-cell development.

Strategic Rationale

Martine Rothblatt, Ph.D., Chairperson and Chief Executive Officer of United Therapeutics, stated that Thymmune's platform complements the company's UThymoKidney™ clinical development program. By restoring or modulating T-cell receptor diversity, Thymmune's technology could address the root causes of dozens of life-threatening diseases, including transplant tolerance and immune-mediated conditions.

Stan Wang, M.D., Ph.D., Chief Executive Officer and Founder of Thymmune Therapeutics, emphasized United Therapeutics' leadership in organ alternatives and cell-based technologies as a key factor in the partnership. The collaboration aims to advance Thymmune's platform toward broad clinical impact.

Financial Terms

Component	Amount
Upfront cash payment	$140 million
Potential earn-out payments	Up to $160 million
Milestone deadline	End of 2031

The acquisition is subject to customary post-closing adjustments. Thymmune's technology holds potential for enhancing longevity in older adults with diminished T-cell function, further broadening the scope of thymic regenerative medicine.

United Therapeutics Corporation has received U.S. Food and Drug Administration (FDA) premarket approval for the LungFX device, the first technology authorized for centralized ex vivo lung perfusion (EVLP). This approval enables the assessment of donor lungs outside the body before transplantation, specifically targeting organs that cannot be placed for transplant through standard direct-to-recipient procurement procedures. The device is intended to reduce the high percentage of donor lungs that are currently discarded rather than used.

The premarket approval was submitted by Lung Bioengineering Inc., a wholly owned subsidiary of United Therapeutics. The submission included comprehensive safety and effectiveness data supporting the use of LungFX to perform EVLP in a centralized facility. LungFX provides normothermic perfusion and ventilation of procured donor lungs that were initially stored with cold static preservation solution. It is indicated for the re-assessment of deceased-donor lungs for male and female patients aged 18 years or older with end-stage lung disease. Under the approved labeling, lungs transplanted following LungFX evaluation must undergo a second period of cold storage, with total preservation time not intended to exceed 20 hours.

Operational Details and Safety

Lung Bioengineering has performed 1,100 EVLP procedures using other approved devices to date, with 600 lungs accepted for transplant. The company expects to integrate LungFX into its available services in 2027. The device is designed to allow transplant programs to access EVLP capabilities without building them within their own hospitals, as only qualified Lung Bioengineering personnel can operate the device and only trained physicians can evaluate lung suitability after the procedure.

Metric	Value
Total EVLP procedures performed	1,100
Lungs accepted for transplant	600
Expected service availability	2027

The FDA approval includes specific warnings regarding clinical outcomes. In the CLES Pivotal Study, the observed 12-month survival rate among recipients of LungFX lungs did not meet the pre-specified performance goal. Rates of 12-month overall mortality and lung graft-related mortality were higher in EVLP subjects compared to non-EVLP control subjects. Consequently, physicians are advised to fully consider the risks and benefits before proceeding with LungFX organ preservation.

Strategic Implications

Martine Rothblatt, Chairperson and Chief Executive Officer of United Therapeutics, emphasized that the approval is a significant step toward reducing the number of donor lungs left behind. The company views this as a milestone in its path toward using advanced technologies to create an unlimited supply of transplantable organs. Dr. Kenneth McCurry, director of the Cleveland Clinic Enterprise Transplant Center and an investigator in the LungFX pivotal trial, noted that the technology provides transplant teams with additional clinical information to determine donor lung suitability. Brandi Zofkie, associate vice president of Lung Bioengineering, highlighted that LungFX is the first EVLP device approved specifically for centralized facilities. Lung Bioengineering operates centralized EVLP facilities in Silver Spring, Maryland, and Jacksonville, Florida.